Celimmune Report issue

For profit Phase 2
Founded: Bethesda MD United States (2015)
Status: Acquired by Amgen (2017)

Organization Overview

First Clinical Trial
2016
NCT02637141
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

prv-015 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Celiac Disease (Phase 2)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1